Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $32.00 at Barclays

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective decreased by equities research analysts at Barclays from $43.00 to $32.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price target would suggest a potential upside of 115.49% from the stock’s current price.

RARE has been the topic of a number of other reports. JPMorgan Chase & Co. downgraded Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $80.00 to $36.00 in a research note on Thursday. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Wells Fargo & Company downgraded shares of Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $50.00 to $18.00 in a research report on Thursday. Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $37.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Royal Bank Of Canada lowered shares of Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $36.95.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $14.85 on Friday. Ultragenyx Pharmaceutical has a 52 week low of $13.81 and a 52 week high of $39.89. The firm’s fifty day moving average is $28.07 and its 200-day moving average is $25.04. The firm has a market cap of $1.46 billion, a P/E ratio of -2.54 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business’s quarterly revenue was up 28.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.17) earnings per share. As a group, sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -3.97 earnings per share for the current year.

Insider Activity

In related news, Director Corsee Sanders sold 2,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the sale, the director owned 21,095 shares in the company, valued at $528,429.75. This represents a 8.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Karah Parschauer sold 1,899 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the transaction, the executive vice president directly owned 94,462 shares in the company, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $355,746,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Ultragenyx Pharmaceutical in the 2nd quarter worth about $6,397,000. Deutsche Bank AG bought a new position in Ultragenyx Pharmaceutical during the second quarter worth about $5,503,000. Corient Private Wealth LP purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth about $4,644,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $6,098,000. Institutional investors own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see potential value after the selloff. Jefferies, Citi, TD Cowen, Canaccord, Cantor Fitzgerald and HC Wainwright retained buy or overweight ratings, although they substantially reduced their price targets. Ultragenyx stock downgraded trial setback
• Positive Sentiment: Ultragenyx’s commercial rare-disease portfolio remains an important potential support for the business, and commentary highlighted the possibility that the company could recover if marketed products continue to grow. Ultragenyx Stock Sinks on Drug Trial Failure
• Positive Sentiment: Unusually heavy call-option activity and speculative comments that Ultragenyx could become a takeover target, including by larger rare-disease companies, offered a possible source of near-term support but do not represent confirmed corporate activity.
• Neutral Sentiment: Analyst views became sharply more cautious: Wells Fargo, JPMorgan, Baird, Evercore, William Blair and Bank of America downgraded the stock or moved to more conservative ratings. Revised targets ranged from $16 to $37, indicating significant uncertainty despite implied upside from the recent price.
• Neutral Sentiment: Management is expected to evaluate “significant” cost reductions and reconsider the future of the Angelman syndrome program, which could preserve cash but also reduce research investment. Ultragenyx to weigh significant cost cuts
• Negative Sentiment: The Aspire study failed to achieve both its primary endpoint—change in Bayley-4 cognitive raw score—and key secondary endpoint, the Multidomain Responder Index. The results place apazunersen’s regulatory and commercial prospects in serious doubt. Ultragenyx Announces Phase 3 Aspire Results
• Negative Sentiment: The late-stage failure triggered a broad analyst reset and raised concerns about Ultragenyx’s pipeline concentration, future revenue growth and continued cash burn. Ultragenyx shares crater after Angelman syndrome drug fails

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.